Aventis

Pfizer talking with CROs to fill R&D hub

Wednesday, March 16, 2011 12:33 PM

A U.K. task force—assembled to salvage as many R&D jobs at Sandwich as it can before Pfizer completes its planned exit—has confirmed that the pharma giant is in discussions with CROs that may step in to hire some of the 2,400 workers being let go, according to Fierce Biotech.

More... »

FDA approves generic Taxotere

Friday, March 11, 2011 01:47 PM

Hospira has won approval for the first U.S. generic version of Sanofi-aventis’ Taxotere cancer drug, according to a Reuters report.

More... »

Genzyme sells pharmaceuticals segment

Monday, March 7, 2011 10:49 AM

Cambridge, Mass.-based Genzyme has completed the sale of its pharmaceutical intermediates business to Germany's International Chemical Investors Group for an undisclosed amount, according to BIOSmartBrief.

More... »

AstraZeneca joins quest for TB therapies

Monday, March 7, 2011 10:43 AM

AstraZeneca became the newest member of a $22 million multi-member partnership to find new therapies for tuberculosis. The current remedies for the disease have been in use for over 50 years, and require several months or years of treatment. But with the expertise and help of companies including AZ and Sanofi-aventis, and academic partners University of Cambridge and institutions in Pavia, Italy and Uppsala, Sweden, the group hopes to cut treatment time.

More... »

Two CROs honored for employee training programs

Thursday, March 3, 2011 06:16 AM

Two global contract research organizations—Quintiles Transnational and Kendle—have been named to the Training Top 125 list, which recognizes excellence in employer-sponsored training and development programs.

More... »

FDA issues warning letter to Sanofi-aventis

Tuesday, March 1, 2011 08:00 AM

The FDA has warned Sanofi-Aventis’ U.S. unit for failing to submit reports of possible serious drug side effects in a timely manner. In a Jan. 28 letter made public last week, the FDA said an early response from the drugmaker and its "promised corrective actions are inadequate to address the deficiencies."

More... »

Sanofi’s $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend

Tuesday, February 22, 2011 10:06 AM

Could last Wednesday’s $20 billion Sanofi-aventis acquisition of Genzyme signal the beginning of an industry trend in which big pharmaceutical companies stop buying each other and start buying robust biotechnology firms?

More... »

Covance and Sanofi-aventis ink landmark 10-year, $2.2 billion R&D outsourcing partnership

Monday, October 4, 2010 10:01 AM

Hailed as the largest outsourcing partnership between a contract research organization (CRO) and a pharmaceutical company, Covance and Sanofi-aventis have signed a 10-year agreement in which the CRO will provide France’s largest pharmaceutical company with a wide range of research and drug development services, and receive between $1.2 billion and $2.2 billion in revenue.

More... »

Phase Forward Appoints First Chief Privacy Officer

Thursday, December 24, 2009 07:40 AM

Phase Forward appointed long-time employee Michael Owings to the new role of chief privacy officer. Owings will oversee all privacy and data protection processes affecting Phase Forward’s customers and employees, and ensure compliance with all relevant regulations. He will also continue his duties as vice president, quality and regulatory compliance—a title he’s held since 2004.

More... »